The latest international news, analysis and features on the HIV epidemic from Avert. Share your views and expertise with your peers in the comments box below the articles.
For lots of people, the ‘fear of the unknown’ stops them from accessing sexual health testing and support. In this episode, Jim and Andy remember how they used to feel going into clinics and where they went for support.
Fewer people living with HIV and hepatitis C (HCV) who have a history of injecting drug use and unstable housing are on newer, more effective HCV medication, new research from France finds.
Men who don’t disclose same-sex sexual behaviour have different HIV transmission patterns compared to other men who have sex with men (MSM) and heterosexual men.
Social support found to be the most effective component in stigma interventions among African American women living with HIV. Workshop activities themselves were not associated with significant change in experiences of stigma.
A new study among people entering prison in the USA suggests ‘opt-out’ testing approaches for HIV and hepatitis C virus (HCV) may need reconsideration.
Increasing numbers of people co-infected with HIV and hepatitis C (HCV) are accessing treatment for HCV as antivirals become more effective – but challenges beyond increasing access, remain.
Findings show that fear of prosecution can drive new infections, as it puts men off knowing their status.
Research reveals that most gay and bisexual men who stop taking pre-exposure prophylaxis (PrEP) in the USA do so because it is too expensive or they see themselves as no longer having a need for it.
Nearly one-fifth (19%) of all cancers among people living with HIV could have been avoided by not smoking according to a recent study among people living with HIV in North America.
With three in ten gay men living with HIV engaging in chemsex in the last year in the UK, understanding its association with the country’s HIV and STI epidemics is critical to put an end to new infections.
New research compares treatment outcomes of single versus multiple tablet regimes, raising questions around cost-effectiveness.